Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
We Can Medicines CoROCO:6929 -0.45%46 Gross Margin % is 31.88% as of Dec. 2025, which is 3% below its 10-year median of 32.98. GuruFocus rates ROCO:6929 with a GF Score™ of 46/100 and a GF Value™ of NT$40.73 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,907 Consumer Packaged Goods companies, We Can Medicines Co ranks better than 64.81% on this metric.
The historical rank and industry rank for We Can Medicines Co's Gross Margin % or its related term are showing as below:
ROCO:6929'
s Gross Margin % Range Over the Past 10 Years
Min: 32.57 Med: 32.98 Max: 33.77
Current: 33.15
During the past 6 years, the highestGross Margin % of We Can Medicines Co was 33.77%. The lowest was 32.57%. And the median was 32.98%.
ROCO:6929's Gross Margin % is ranked better than 64.81% of 1907
companies
in the Consumer Packaged Goods industry
Industry Median: 26.36
vs ROCO:6929: 33.15
We Can Medicines Co had a gross margin of 31.88% for the quarter that ended in Dec. 2025 => Competition eroding margins
The 5-Year average Growth Rate of Gross Margin for We Can Medicines Co was 0.40% per year.
We Can Medicines Co (ROCO:6929) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
We Can Medicines Co had a gross margin of 31.88% for the quarter that ended in Dec. 2025 => Competition eroding margins
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
We Can Medicines Co Gross Margin % Related Terms
We Can Medicines Co Gross Margin % Historical Data
* Premium members only.
The historical data trend for We Can Medicines Co's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, We Can Medicines Co's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
We Can Medicines Co Gross Margin % vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, We Can Medicines Co's Gross Margin % distribution charts can be found below:
* The bar in red indicates where We Can Medicines Co's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
We Can Medicines Co (ROCO:6929) has a Gross Margin % of 31.88% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on We Can Medicines Co and its competitors. This is near median its historical median of 32.98. Over the past decade, We Can Medicines Co's Gross Margin % has ranged from 32.57 to 33.77. According to the industry distribution chart, We Can Medicines Co ranks #671 out of 1907 companies in the Consumer Packaged Goods industry, placing it in the top 35.2%.
Is We Can Medicines Co's Gross Margin % too high?
We Can Medicines Co's current Gross Margin % of 31.88% is near median its 10-year median of 32.98. Over the past 10 years, this metric has ranged from a low of 32.57 to a high of 33.77. The Consumer Packaged Goods industry median Gross Margin % is 26.36. We Can Medicines Co's value of 31.88% is 20.9% above this industry median. Based on the distribution chart, We Can Medicines Co ranks #671 out of 1907 companies in the Consumer Packaged Goods industry, which is above the industry midpoint. Overall, We Can Medicines Co has a GF Score™ of 46/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does We Can Medicines Co's Gross Margin % compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, We Can Medicines Co ranks #671 out of 1907 companies for Gross Margin %. This puts We Can Medicines Co in the upper half of its industry. The industry median Gross Margin % is 26.36. We Can Medicines Co's value of 31.88% is 20.9% above this benchmark. Historically, We Can Medicines Co's own Gross Margin % has ranged from 32.57 to 33.77 over the past decade. While the company's 10-year median is 32.98 vs. the industry median of 26.36, We Can Medicines Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Consumer Packaged Goods company?
The median Gross Margin % among Consumer Packaged Goods companies is 26.36, based on 1,907 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. We Can Medicines Co's current Gross Margin % of 31.88% is 20.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on We Can Medicines Co and its competitors. For the Consumer Packaged Goods industry, the median Gross Margin % is 26.36 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. We Can Medicines Co's current Gross Margin % is 31.88%, which is near median its own 10-year median of 32.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is We Can Medicines Co stock overvalued right now?
Based on GuruFocus' analysis, We Can Medicines Co (ROCO:6929) is currently considered Possible Value Trap. The stock's GF Value™ is NT$40.73, compared to a current price of NT$22.30 — trading 45.2% below its estimated fair value. The current Gross Margin % is 31.88%, which is near median its 10-year median of 32.98 and 20.9% above the Consumer Packaged Goods industry median of 26.36. We Can Medicines Co's overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For We Can Medicines Co (ROCO:6929), the current Gross Margin % is 31.88% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is We Can Medicines Co (ROCO:6929) Overvalued in 2026?
Based on GuruFocus' analysis, We Can Medicines Co stock appears to be undervalued.
The current stock price of NT$22.30 is trading 45.2% below its estimated GF Value™ of NT$40.73.
GuruFocus considers We Can Medicines Co to be Possible Value Trap.
Key valuation signals for ROCO:6929:
Gross Margin %: 31.88% (near median its 10-year median of 32.98)
GF Value™: NT$40.73 vs. price of NT$22.30 (45.2% below fair value)
Industry Position: 20.9% above the Consumer Packaged Goods median (#671 of 1907)
No single metric tells the full story. See the ROCO:6929 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
We Can Medicines Co Ltd is a Taiwan-based company mainly engaged in the operation of chain cosmeceutical drugstores. The Company's main products include pharmaceuticals and health food, maternity and infant products, medical supplies, beauty cosmetics, and daily necessities.
46GF Score
Get the complete analysis for ROCO:6929
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6929 has been successfully added to your 
